Business Context and Reporting Period
This Form 8-K Current Report from DarioHealth Corp. covers the date of March 31, 2017. The filing reports the entry into a material definitive agreement regarding a public offering of common stock.
Key Financial Metrics
The filing details a firm commitment public offering with the following terms:
- Shares Offered: 1,450,000 shares of common stock.
- Public Offering Price: $3.10 per share.
- Aggregate Gross Proceeds: Approximately $4,500,000.
- Representative's Warrants: 36,250 shares exercisable at $3.875 per share for a five-year term.
The filing text does not provide clear values for revenue, profit, cash flow, margins, existing debt, or liquidity positions as this report focuses on the capital raise event rather than periodic financial performance.
Material Changes
The primary material change is the execution of an underwriting agreement with Aegis Capital Corp. as the representative of the underwriters. This agreement facilitates the issuance of new equity and warrants, altering the company's capital structure upon closing.
Guidance, Outlook, and Risks
Management commentary is limited to the terms of the underwriting agreement and the inclusion of a press release (Exhibit 99.1) for additional details. The filing notes standard risks associated with securities offerings, including customary representations, warranties, indemnification obligations, and termination provisions. No specific forward-looking guidance on future revenue or operational milestones is provided in this text.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and commissions.
- Confirm the dilution impact of the 1,450,000 new shares and the 36,250 warrant shares on existing shareholders.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific conditions to closing and termination rights.
- Check the status of the shelf registration statement (File No. 333-212644) referenced for the offering.